- Home
- BBT vs VCEL Comparison
BBT vs VCEL Comparison
Compare BBT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBT | VCEL |
|---|---|---|
| Founded | 1846 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BBT | VCEL |
|---|---|---|
| Price | $31.94 | $44.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $33.25 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 732.4K | 460.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $400,000,000.00 | $276,259,000.00 |
| Revenue This Year | $77.88 | $19.40 |
| Revenue Next Year | $4.31 | $18.24 |
| P/E Ratio | $24.52 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $22.81 | $28.95 |
| 52 Week High | $32.83 | $49.32 |
Technical Indicators
Market Signals| Indicator | BBT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 46.04 |
| Support Level | $27.96 | $32.44 |
| Resistance Level | $32.83 | $49.04 |
| Average True Range (ATR) | 0.59 | 1.56 |
| MACD | 0.08 | -0.39 |
| Stochastic Oscillator | 79.54 | 16.94 |
Price Performance
Historical ComparisonAbout BBT Beacon Financial Corporation
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.